Aspire Bariatrics Inc.

The highly competitive global market for minimally invasive weight loss (bariatric) devices is predicted to rise from $137m in 2016 to $290m by 2021, a CAGR of 16%. This is driven in large part by the

Four original PMAs were approved in June, making for a total of 19 approvals in the first half of 2016. There were no panel-track supplement approved last month, but there have been nine approvals of

Aspire Bariatrics Inc. expects to start placing its AspireAssist stomach-draining device for obese patients at clinical facilities within the next month now that it has gained FDA approval. "We ar

FDA OK'd its second obesity device this year on July 28, with the PMA approval for ReShape Medical Inc. 's ReShape weight-loss system. On the same day, Aspire Bariatrics Inc. announced a PMA